Akebia Therapeutics (AKBA) Misses Q4 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.10), $0.03 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $46.49 million versus the consensus estimate of $49.57 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Befesa SA (BFSA:GR) PT Lowered to EUR35 at Deutsche Bank
• Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight